Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, March 28, 2023
[ Tue, Mar 28th 2023
] - WOPRAI
[ Tue, Mar 28th 2023
] - WOPRAI
[ Tue, Mar 28th 2023
] - WOPRAI
[ Tue, Mar 28th 2023
] - WOPRAI
Mon, March 27, 2023
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
[ Mon, Mar 27th 2023
] - WOPRAI
Judah Frommer Reiterated (ATAI) at Buy and Held Target at $9 on, Mar 27th, 2023
Judah Frommer of Credit Suisse, Reiterated "Atai Life Sciences N.V." (ATAI) at Buy and Held Target at $9 on, Mar 27th, 2023.
Judah has made no other calls on ATAI in the last 4 months.
There are 2 other peers that have a rating on ATAI. Out of the 2 peers that are also analyzing ATAI, 0 agree with Judah's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Judah
- Patrick Trucchio of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $20 on, Thursday, January 19th, 2023
- Neena Bitritto-Garg of "Citigroup" Maintained at Strong Buy with Decreased Target to $10 on, Monday, January 9th, 2023
